---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-039883"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:24:30.294017+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M

## Summary
- Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.
- Closed sale of PRV for $150.0M on April 1, boosting cash to $217.7M as of June 30.
- Non-cash impairment of OLPRUVA intangible assets $58.7M and inventory obsolescence $11.7M.
- Adjusted net loss $(3.2)M ($(0.06)/share) excluding PRV sale and impairment charges.
- MIPLYFFA launch: 7 new enrollment forms in Q2, total 129 since launch; market access 52%.

## SEC filing metadata
- accession: 0001628280-25-039883
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000162828025039883/0001628280-25-039883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000162828025039883/zvra-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-039883
- JSON: https://secwatch.observer/filing/0001628280-25-039883.json
- Plain text: https://secwatch.observer/filing/0001628280-25-039883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.